about
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancerEstrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancerA semantic grid infrastructure enabling integrated access and analysis of multilevel biomedical data in support of postgenomic clinical trials on cancer.Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?Comparison of prognostic gene expression signatures for breast cancerThe Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international groupA fuzzy gene expression-based computational approach improves breast cancer prognosticationConsistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response.HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Multiple-input multiple-output causal strategies for gene selection.Genomic index of sensitivity to endocrine therapy for breast cancer.Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysisTransfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.A three-gene model to robustly identify breast cancer molecular subtypesSubclonal diversification of primary breast cancer revealed by multiregion sequencing.DNA methylation profiling reveals a predominant immune component in breast cancers.Breast cancer gene expression profiling: clinical trial and practice implications.Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patientsUncovering the genomic heterogeneity of multifocal breast cancer.Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.Gene expression profiling in breast cancer.Predicting risk of breast cancer recurrence using gene-expression profiling.Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.CD4⁺ follicular helper T cell infiltration predicts breast cancer survivalNext-generation sequencing in breast cancer: first take home messages.Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation.Genomic grade index is associated with response to chemotherapy in patients with breast cancer.Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.'In silico' oncology for clinical decision making in the context of nephroblastoma.
P50
Q24644185-7FA76BB9-B015-4C4B-B5D7-4960A8B872B1Q28291343-5CF48D38-9CA3-430E-AA37-0A976D24AC32Q31022382-313D6151-C1A5-4299-9771-36821ADBC0C9Q31149936-F72DF9DD-BD1D-4FEC-B332-93D428197CECQ33337206-4CC5042F-5FE0-418C-B736-D3227FD3B340Q33352632-0EC2DE36-0114-409B-A7CE-31A80780E8B5Q33362164-340BFF41-B580-49D7-87B4-59344A4B9864Q33477635-F161FF5E-B43F-4FD8-BEE8-D0B32B5BAD2DQ33501853-2FA4FC87-5572-4E09-AE7F-D85FBAFAAFD9Q33854251-E058C442-438C-49F6-A6B8-BB6BAFB3CA26Q33861620-9DA9A1C8-C3EA-4425-BD3B-A5AB23FD9094Q33974305-79AA92AC-6AC5-49CF-AD83-858DB3084426Q34019589-556EEA68-7F93-4084-A075-6D36F7D3EDC7Q34046731-336B0E1A-2A98-4058-BA8E-405E6FE203AAQ34083912-ACD309A7-6F3E-4354-80B5-067E26001491Q34193932-E9E99D01-8AFD-479D-99CD-FBC079D4348FQ34701521-2D0CB2CD-18C6-41D7-B1F9-B3FDD6ECEBE2Q34897615-2188B5EB-B066-4547-8255-1702E1420B11Q35234637-B7E86FA8-2E04-478A-88F1-1E37DB72C2F0Q35610564-63D8AFFD-12D5-4E25-AEA2-FB840665D6D1Q35655229-256A7E49-A349-40FB-B5F3-2E2B00B6E256Q35664110-C0A5FA98-D65C-405C-9430-F93DB906660CQ35733734-3DFD0170-2A41-4EE4-8E3E-6FB4230831FCQ35769036-F24F3B95-A677-430A-A5D3-F70DD8BC78E9Q35847434-8B4D1CE0-0016-487E-A649-3403E7377774Q36038847-1A133241-F3CF-43C4-9F3A-5FEBB7B7C14CQ36050579-E1E1B094-AD30-44A6-A8FA-F3030FAC089BQ36171157-58C7EE20-6930-40F9-BFD8-3591D90405D8Q36404728-39B829AF-1AAB-411D-A187-4834CD6E8EB2Q36557582-C5F012BE-6106-4FCC-B741-EC0D09AE5BD8Q36612742-6A5A64A7-BE46-4BA1-8962-51549EF72E23Q36691795-CAE6DE76-3A9B-4BCB-94B2-DD36C93B66F0Q36739364-B1DA78D1-1594-44E5-B8ED-A6D374AE44F8Q36955113-AC489DF6-835E-44B0-8AFF-208DFD4EAC5EQ36966923-BC405076-F4AD-4102-8FBE-1A2E1D390F97Q37019650-15CEEF46-1FE2-42A2-93D0-4C91102E5901Q37149898-3A5FD303-EE5B-42DA-B47B-C4E28ED781D5Q37278382-DC95D25C-3D74-4446-805F-3F9D4788BAE1Q37315121-67B3C5CE-25AE-410E-86C1-9B8F96BADF6EQ37479394-F9193971-8978-4F9C-AB7C-BE337AF603B9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christine Desmedt
@ast
Christine Desmedt
@en
Christine Desmedt
@es
Christine Desmedt
@nl
Christine Desmedt
@sl
type
label
Christine Desmedt
@ast
Christine Desmedt
@en
Christine Desmedt
@es
Christine Desmedt
@nl
Christine Desmedt
@sl
prefLabel
Christine Desmedt
@ast
Christine Desmedt
@en
Christine Desmedt
@es
Christine Desmedt
@nl
Christine Desmedt
@sl
P1053
P-7438-2017
P106
P21
P31
P3829
P496
0000-0002-5223-5579